Testing for COVID-19: Increasing testing supply

What Canada is doing

Canada is mobilizing industry and providing support for research, market approval, manufacturing and access to medical supplies. We're working proactively with companies that are developing new and innovative testing technologies. We're also engaging with international regulators to share knowledge about new developments related to testing.

Increasing testing options

Health Canada reviews testing devices to assess their safety, effectiveness and quality before they're authorized for sale in Canada. For a test to be authorized by Health Canada, it must be submitted for review by the manufacturer. To date, Health Canada has authorized over 50 different COVID-19 tests. We also continue to expedite the review of COVID-19 tests, including new testing options.

Health Canada is currently prioritizing the review of:

tests that can be used at point-of-care to provide rapid diagnostic or monitoring results, including antigen tests
saliva tests (tests that use spit as the sample instead of a sample from the nose or throat)

Health Canada has received a number of antigen test applications that are under priority review. Antigen tests detect specific proteins on the surface of the virus and provide rapid results.

A small number of saliva tests have been submitted to Health Canada and are under priority review. Health Canada hasn't authorized any tests for use with saliva at this time.

Health Canada will expedite the review of any new testing technologies submitted by manufacturers, including at-home test kits (also known as "self-testing"). For at-home test kits, the manufacturer must provide data to show the test is safe and effective for Canadians to use without health care professional supervision.

In all cases, companies must provide evidence that the test is accurate and reliable before Health Canada will authorize it. Health Canada has provided guidance to manufacturers on the authorization requirements for different types of tests such as antibody tests and antigen tests.

Securing rapid tests

Public Services and Procurement Canada has purchased rapid tests on behalf of and at the direction of the Public Health Agency of Canada. This purchase ensures that the federal government can increase testing capacity with authorized, proven and effective technologies. Explore COVID-19 rapid test purchase agreements.

Rapid tests distributed in Canada

The Government of Canada has purchased over 59 million units of the following rapid tests: Abbott Panbio, Abbott ID Now, BD Veritor, Quidel Sofia and BTNX.

The tables below show the number of COVID-19 rapid tests that have been shipped in provinces and territories as of October 08, 2021 (deployment data as of October 07, 2021). The data for “tests deployed” show the quantities of rapid tests that have been distributed to their final point-of-care setting where they will be administered to patients. The data for “tests used” depict how many of those rapid tests have been administered.

There is a delay in the reporting on the deployment of rapid tests. This is due to the time when tests are:

shipped and delivered to provinces and territories
redistributed throughout each jurisdiction

The numbers listed are updated once a week.

Canada

Distribution of tests in Canada
Product name	Tests received	Tests shipped to PTs and Federal Allocation	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}	Strategic Supply
Abbott ID Now	6,611,544	4,510,872	1,803,307	840,231	1,848,096
Abbott Panbio	37,727,900	31,521,138	30,050,520	9,302,758	253,950
BD Veritor	11,599,980	7,008,000	3,942,419	603,621	2,036,760
Quidel Sofia	850,000	90,600	0	1,056	759,400
BTNX	2,249,350	0	0	0	249,350
Total	59,038,774	43,130,610	35,796,246	10,747,666	5,147,556
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Newfoundland and Labrador

Distribution of tests for Newfoundland and Labrador
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	85,432	86,208	9,177
Abbott Panbio	304,200	304,375	15,258
BD Veritor	0	0	0
BTNX	0	0	0
Total	389,632	390,583	24,435
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Prince Edward Island

Distribution of tests for Prince Edward Island
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	365,688	no information provided	188,567
Abbott Panbio	106,000	no information provided	no information provided
BD Veritor	0	0	0
BTNX	40,000	0	0
Total	511,688	no information provided	188,657
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Nova Scotia

Distribution of tests for Nova Scotia
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	106,512	1,491	1,491
Abbott Panbio	1,421,125	749,214	469,264
BD Veritor	540,360	63,439	63,439
BTNX	0	0	0
Total	2,067,977	814,144	534,194
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

New Brunswick

Distribution of tests for New Brunswick
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	78,912	12,736	328
Abbott Panbio	1,471,200	520,075	62,558
BD Veritor	0	0	0
BTNX	250,000	0	0
Total	1,800,112	532,811	62,886
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Quebec

Distribution of tests for Quebec
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	822,816	751,176	239,909
Abbott Panbio	3,563,750	2,908,144	9,954
BD Veritor	911,280	604,560	35,419
BTNX	0	0	0
Total	5,297,646	4,263,880	285,282
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Ontario

Distribution of tests for Ontario
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	1,218,144	473,954	82,298
Abbott Panbio	17,179,738	25,471,720	7,011,292
BD Veritor	4,033,740	1,063,865	190,857
Quidel Sofia	73,200	0	0
BTNX	750,000	0	0
Total	23,254,822	27,009,539	7,284,447
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used and may also include tests purchased by the province. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date and may also include tests purchased by the province. Return to footnote referrer

Manitoba

Distribution of tests for Manitoba
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	176,448	21,024	no information provided
Abbott Panbio	787,825	407,475	no information provided
BD Veritor	695,010	11,520	no information provided
BTNX	0	0	no information provided
Total	1,659,283	440,019	no information provided
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used and may also include tests purchased by the province. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date and may also include tests purchased by the province. Return to footnote referrer

Saskatchewan

Distribution of tests for Saskatchewan
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	348,446	150,528	125,625
Abbott Panbio	2,854,875	1,708,400	232,114
BD Veritor	1,351,770	50,790	0
BTNX	500,650	0	0
Total	5,055,741	1,909,718	357,739
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Alberta

Distribution of tests for Alberta
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	537,912	251,974	154,878
Abbott Panbio	3,599,522	3,480,412	860,363
BD Veritor	936,720	985,058	201,276
BTNX	459,350	0	0
Total	5,533,504	4,717,444	1,216,517
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

British Columbia

Distribution of tests for British Columbia
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	626,976	79,080	16,801
Abbott Panbio	2,130,850	766,051	142,219
BD Veritor	389,880	51,090	27,147
BTNX	0	0	0
Total	3,147,706	896,221	186,167
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Yukon

Distribution of tests for Yukon
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	15,720	no information provided	no information provided
Abbott Panbio	13,600	no information provided	no information provided
BD Veritor	0	0	0
BTNX	0	0	0
Total	29,320	0	0
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Northwest Territories

Distribution of tests for Northwest Territories
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	63,960	4,944	4,188
Abbott Panbio	34,800	3,825	136
BD Veritor	0	0	0
BTNX	0	0	0
Total	98,760	8,769	4,324
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Nunavut

Distribution of tests for Nunavut
Product name	Tests received	Tests deployed^{Footnote *}	Tests used (as reported)^{Footnote **}
Abbott ID Now	25,416	5,424	no information provided
Abbott Panbio	25,400	14,400	no information provided
BD Veritor	0	0	no information provided
BTNX	0	0	no information provided
Total	50,816	19,824	no information provided
Footnote * The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote * referrer Footnote The tests used information shows data that has been reported to Health Canada to date. Return to footnote referrer

Federal allocation

Distribution of tests for Federal Operations^{Footnote *}
Product name	Tests received	Tests deployed^{Footnote **}	Tests used (as reported)^{Footnote ***}
Abbott ID Now	280,136	156,408	16,879
Abbott Panbio	434,350	253,900	89,945
BD Veritor	11,600	0	0
Quidel Sofia	8,400	0	1,056
Total	734,486	410,308	107,880
Footnote * The federal operations numbers include tests distributed to federal government departments such as: Department of National Defence (DND), Correctional Services Canada (CSC), the Public Health Agency of Canada (PHAC), as well as Northern, remote and Indigenous communities. Return to footnote * referrer Footnote The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote referrer Footnote * The tests used information shows data that has been reported to Health Canada to date. Return to footnote * referrer

Direct to organizations for workplace screening^{Footnote *}
Product name	Tests available	Tests deployed^{Footnote **}	Tests used (as reported)^{Footnote ***}
Abbott ID Now	24,984	0	0
Abbott Panbio	2,826,900	2,727,900	409,655
BD Veritor	995,080	1,804,650	85,483
Quidel Sofia	9,000	0	0
Total	3,855,964	4,532,550	495,138
Footnote * Federal distribution numbers include tests shipped to businesses, non-profit organizations, crown corporations, and distribution partners such as pharmacies and the Canadian Red Cross. Return to footnote * referrer Footnote The test deployed information show the number of tests that have been distributed to their final point-of-care setting where they will be administered to patients. These numbers do not show how many tests have been used. Return to footnote referrer Footnote * The tests used information shows data that has been reported to Health Canada to date. Return to footnote * referrer

Supporting provincial and territorial COVID-19 testing capacity

The federal government is providing $4.28 billion to the provinces and territories. This money is to help them conduct testing, perform contact tracing and share public health data that will help fight the pandemic. The goal is to ensure they have the capacity to test up to 200,000 people each day, nationwide.

Canada is also providing funding and support to improve and modernize data management across Canada. This support is to help all levels of government coordinate their efforts to contain the virus.

The table below shows the current capacity for each province and territory compared to the capacity target agreed to under the Safe Restart Agreement.

The national capacity target of about 200,000 tests each day is based on modelling. This modelling exercise indicates this capacity is enough to meet the expected demand for testing.

Provincial and territorial COVID-19 testing capacity

Testing capacity reported as of September 30, 2021.

Please consult the Coronavirus disease 2019 (COVID-19): Epidemiology update for daily and weekly updates on the average number of people tested.

In circumstances where capacity was not reported, the previous week's capacity was indicated (see *).

Newfoundland and Labrador: Target 2,500 - 3,000

COVID-19 testing capacity for Newfoundland and Labrador (Target 2,500 - 3,000^Footnote***)
Date	Projected daily maximum testing capacity
2020-09-03	1,450
2020-09-10	1,450
2020-09-17	1,450
2020-09-24	1,450
2020-10-01	1,450
2020-10-08	1,450
2020-10-15	1,450
2020-10-22	1,450
2020-10-29	1,450
2020-11-03	1,450
2020-11-10	1,450
2020-11-17	1,450
2020-11-24	1,450
2020-12-01	1,450
2020-12-08	1,450
2020-12-15	1,450
2020-12-22	1,450
2020-12-29	1,450
2021-01-05	1,450
2021-01-12	1,450
2021-01-19	1,450
2021-01-26	1,450
2021-02-02	1,450
2021-02-09	1,700
2021-02-16	1,700^{Footnote *}
2021-02-23	1,700
2021-03-02	1,700
2021-03-09	1,700
2021-03-16	1,700
2021-03-23	2,100
2021-03-29	2,100
2021-04-06	2,100
2021-04-12	2,500
2021-04-19	2,500
2021-04-26	2,500
2021-05-03	2,700
2021-05-10	2,700
2021-05-17	2,700
2021-05-24	2,700
2021-05-31	2,700
2021-06-30	2,700
2021-07-31	2,700
2021-08-31	2,700
2021-09-30	2,700
Footnote * Target updated October 6 at the request of Newfoundland and Labrador Return to footnote* referrer

Prince Edward Island: Target 835

COVID-19 testing capacity for Prince Edward Island (Target 835)
Date	Projected daily maximum testing capacity
2020-09-03	350
2020-09-10	430
2020-09-17	350
2020-09-24	350
2020-10-01	400
2020-10-08	400
2020-10-15	400 (800^Footnote**)
2020-10-22	400 (800^Footnote**)
2020-10-29	400 (800^Footnote**)
2020-11-03	400 (800^Footnote**)
2020-11-10	400 (800^Footnote**)
2020-11-17	400 (800^Footnote**)
2020-11-24	400 (800^Footnote**)
2020-12-01	400 (800^Footnote**)
2020-12-08	400^Footnote* (800^Footnote**)
2020-12-15	400 (800^Footnote**)
2020-12-22	400
2020-12-29	400
2021-01-05	600
2021-01-12	600
2021-01-19	600
2021-01-26	600
2021-02-02	700
2021-02-09	850
2021-02-16	850
2021-02-23	850
2021-03-02	850
2021-03-09	850
2021-03-16	850
2021-03-23	850
2021-03-29	850
2021-04-06	850
2021-04-12	850
2021-04-19	850
2021-04-26	850
2021-05-03	850
2021-05-10	850
2021-05-17	850
2021-05-24	850
2021-05-31	850
2021-06-30	850
2021-07-31	850
2021-08-31	850
2021-09-30	850
Footnote Revised to include the surge testing capacity available on a temporary basis. Return to footnote referrer

Nova Scotia: Target 2,500

COVID-19 testing capacity for Nova Scotia (Target 2,500)
Date	Projected daily maximum testing capacity
2020-09-03	1,500
2020-09-10	1,500
2020-09-17	1,500
2020-09-24	1,500
2020-10-01	1,500
2020-10-08	1,500
2020-10-15	1,500
2020-10-22	1,500
2020-10-29	1,500
2020-11-03	1,500
2020-11-10	1,500
2020-11-17	1,500
2020-11-24	2,500
2020-12-01	2,500
2020-12-08	2,500
2020-12-15	2,500
2020-12-22	2,500
2020-12-29	2,500
2021-01-05	2,500
2021-01-12	2,500
2021-01-19	2,500
2021-01-26	2,500
2021-02-02	2,500
2021-02-09	2,500
2021-02-16	2,500
2021-02-23	2,500
2021-03-02	2,500
2021-03-09	2,500
2021-03-16	2,500
2021-03-23	2,500
2021-03-29	2,500
2021-04-06	2,500
2021-04-12	2,500
2021-04-19	2,500
2021-04-26	2,500
2021-05-03	10,000
2021-05-10	10,000
2021-05-17	10,000
2021-05-24	10,000
2021-05-31	10,000
2021-06-30	10,000
2021-07-31	10,000
2021-08-31	10,000
2021-09-30	10,000

New Brunswick: Target 2,500 - 3,000

COVID-19 testing capacity for New Brunswick (Target 2,500 - 3,000)
Date	Projected daily maximum testing capacity
2020-09-03	1,500
2020-09-10	1,500
2020-09-17	1,500
2020-09-24	1,500
2020-10-01	1,500
2020-10-08	1,500
2020-10-15	1,500
2020-10-22	1,500
2020-10-29	2,000
2020-11-03	2,000
2020-11-10	2,000
2020-11-17	2,000
2020-11-24	2,000^Footnote*
2020-12-01	2,000
2020-12-08	2,000^Footnote*
2020-12-15	2,500
2020-12-22	2,500
2020-12-29	2,500
2021-01-05	2,500
2021-01-12	2,000
2021-01-19	2,000
2021-01-26	2,000
2021-02-02	2,000
2021-02-09	3,000
2021-02-16	3,000
2021-02-23	3,000
2021-03-02	3,000
2021-03-09	3,000
2021-03-16	3,000
2021-03-23	3,000
2021-03-29	3,000
2021-04-06	3,000
2021-04-12	3,000
2021-04-19	3,000
2021-04-26	3,000
2021-05-03	3,000
2021-05-10	3,000
2021-05-17	3,000
2021-05-24	3,000
2021-05-31	3,000
2021-06-30	3,000
2021-07-31	3,000
2021-08-31	3,000
2021-09-30	3,000

Quebec: Target 35,000

COVID-19 testing capacity for Quebec (Target 35,000)
Date	Projected daily maximum testing capacity
2020-09-03	20,000
2020-09-10	20,000
2020-09-17	20,000
2020-09-24	20,000
2020-10-01	20,000
2020-10-08	20,000
2020-10-15	20,000
2020-10-22	20,000
2020-10-29	20,000
2020-11-03	20,000
2020-11-10	20,000
2020-11-17	20,000
2020-11-24	20,000
2020-12-01	20,000
2020-12-08	35,199
2020-12-15	37,142
2020-12-22	38,846
2020-12-29	40,196
2021-01-05	37,972
2021-01-12	39,127
2021-01-19	36,929
2021-01-26	40,084
2021-02-02	40,977
2021-02-09	42,386
2021-02-16	39,497
2021-02-23	43,987
2021-03-02	41,386
2021-03-09	42,758
2021-03-16	42,427
2021-03-23	43,382
2021-03-29	44,037
2021-04-06	46,392
2021-04-12	48,221
2021-04-19	47,959
2021-04-26	47,659
2021-05-03	47,771
2021-05-10	48,098
2021-05-17	48,471
2021-05-24	46,104
2021-05-31	46,338
2021-06-30	46,048
2021-07-31	46,048
2021-08-31	47,653
2021-09-30	47,653

Ontario: Target 78,000

COVID-19 testing capacity for Ontario (Target 78,000)
Date	Projected daily maximum testing capacity
2020-09-03	35,108
2020-09-10	39,690
2020-09-17	42,434
2020-09-24	42,816
2020-10-01	42,942
2020-10-08	50,692
2020-10-15	51,397
2020-10-22	64,340
2020-10-29	67,094
2020-11-03	71,564
2020-11-10	78,964
2020-11-17	80,856
2020-11-24	81,630
2020-12-01	81,630
2020-12-08	74,008
2020-12-15	77,333
2020-12-22	77,333
2020-12-29	77,581
2021-01-05	79,821
2021-01-12	120,608
2021-01-19	120,608
2021-01-26	120,608
2021-02-02	116,000
2021-02-09	116,000
2021-02-16	116,000
2021-02-23	116,000
2021-03-02	116,000
2021-03-09	117,800
2021-03-16	118,400
2021-03-23	118,400
2021-03-29	118,400
2021-04-06	120,200
2021-04-12	120,200
2021-04-19	120,200
2021-04-26	120,200
2021-05-03	120,200
2021-05-10	124,700
2021-05-17	124,700
2021-05-24	124,700
2021-05-31	124,700
2021-06-30	124,700
2021-07-31	124,700
2021-08-31	124,700
2021-09-30	124,700

Manitoba: Target 3,000

COVID-19 testing capacity for Manitoba (Target 3,000)
Date	Projected daily maximum testing capacity
2020-09-03	3,000
2020-09-10	3,000
2020-09-17	3,000
2020-09-24	3,000
2020-10-01	3,000
2020-10-08	3,000
2020-10-15	3,000
2020-10-22	3,000
2020-10-29	3,000
2020-11-03	3,000
2020-11-10	3,000
2020-11-17	3,000
2020-11-24	3,000^Footnote*
2020-12-01	2,841
2020-12-08	2,841^Footnote*
2020-12-15	2,841^Footnote*
2020-12-22	3,500
2020-12-29	3,500
2021-01-05	3,500
2021-01-12	3,500
2021-01-19	3,500
2021-01-26	3,500
2021-02-02	3,500
2021-02-09	3,500^Footnote*
2021-02-16	3,500
2021-02-23	3,500
2021-03-02	3,500
2021-03-09	3,500^Footnote*
2021-03-16	3,500
2021-03-23^Footnote*	3,500
2021-03-29	3,500
2021-04-06	3,500^Footnote*
2021-04-12	3,500^Footnote*
2021-04-19	3,500^Footnote*
2021-04-26	3,500^Footnote*
2021-05-03	3,500^Footnote*
2021-05-10	3,500^Footnote*
2021-05-17	3,500^Footnote*
2021-05-24	3,500^Footnote*
2021-05-31	3,500^Footnote*
2021-06-30	3,500^Footnote*
2021-07-31	3,500^Footnote*
2021-08-31	4,000
2021-09-30	4,000

Saskatchewan: Target 4,000

COVID-19 testing capacity for Saskatchewan (Target 4,000)
Date	Projected daily maximum testing capacity
2020-09-03	1,800
2020-09-10	1,800
2020-09-17	1,800
2020-09-24	1,800
2020-10-01	1,800
2020-10-08	1,800
2020-10-15	1,800
2020-10-22	1,800
2020-10-29	1,800
2020-11-03	1,800
2020-11-10	2,100
2020-11-17	2,700
2020-11-24	2,700
2020-12-01	3,330
2020-12-08	3,450
2020-12-15	3,450
2020-12-22	3,450
2020-12-29	3,450
2021-01-05	3,846
2021-01-12	3,846
2021-01-19	3,846
2021-01-26	3,846
2021-02-02	3,846
2021-02-09	3,846^Footnote*
2021-02-16	3,846^Footnote*
2021-02-23	3,846
2021-03-02	3,846
2021-03-09	3,846
2021-03-16	4,000
2021-03-23	4,500
2021-03-29	4,500
2021-04-06	4,500
2021-04-12	4,500
2021-04-19	4,500
2021-04-26	4,500
2021-05-03	4,500
2021-05-10	4,500
2021-05-17	4,500
2021-05-24	4,500
2021-05-31	4,500
2021-07-31	4,500
2021-08-31	4,500
2021-09-30	3,000

Alberta: Target 22,000

COVID-19 testing capacity for Alberta (Target 22,000)
Date	Projected daily maximum testing capacity
2020-09-03	12,000
2020-09-10	12,000
2020-09-17	12,000
2020-09-24	12,000
2020-10-01	15,500
2020-10-08	22,000
2020-10-15	22,000
2020-10-22	22,000
2020-10-29	22,000
2020-11-03	22,000
2020-11-10	22,000
2020-11-17	22,000
2020-11-24	22,000
2020-12-01	22,000
2020-12-08	22,000^Footnote*
2020-12-15	22,000
2020-12-22	22,000
2020-12-29	22,000
2021-01-05	22,000
2021-01-12	22,000
2021-01-19	22,000
2021-01-26	22,000
2021-02-02	22,000
2021-02-09	22,000
2021-02-16	22,000
2021-02-23	22,000
2021-03-02	22,000
2021-03-09	22,000
2021-03-16	22,000
2021-03-23	22,000
2021-03-29	22,000
2021-04-06	22,000
2021-04-12	22,000
2021-04-19	22,000
2021-04-26	22,000
2021-05-03	22,000
2021-05-10	22,000
2021-05-17	22,000
2021-05-24	22,000
2021-05-31	22,000
2021-06-30	22,000
2021-07-31	22,000
2021-08-31	22,000
2021-09-30	22,000

British Columbia: Target 20,000

COVID-19 testing capacity for British Columbia (Target 20,000)
Date	Projected daily maximum testing capacity
2020-09-03	7,842
2020-09-10	8,581
2020-09-17	7,996
2020-09-24	9,633
2020-10-01	9,714
2020-10-08	10,506
2020-10-15	10,586
2020-10-22	12,840
2020-10-29	13,685
2020-11-03	17,033
2020-11-10	17,333
2020-11-17	18,733
2020-11-24	18,733
2020-12-01	18,733
2020-12-08	18,945
2020-12-15	18,945
2020-12-22	18,945
2020-12-29	18,945
2021-01-05	19,439
2021-01-12	19,439
2021-01-19	19,817
2021-01-26	19,817
2021-02-02	19,817
2021-02-09	19,817
2021-02-16	19,817
2021-02-23	20,617
2021-03-02	20,617
2021-03-09	20,617
2021-03-16	20,617
2021-03-23	21,332
2021-03-29	21,332
2021-04-06	19,932
2021-04-12	18,932
2021-04-19	20,132
2021-04-26	20,132
2021-05-03	20,132
2021-05-10	20,132
2021-05-17	20,132
2021-05-24	20,132
2021-05-31	20,132
2021-06-30	20,132
2021-07-31	20,132
2021-08-31	20,132
2021-09-30	19,628

Yukon: Target 160

COVID-19 testing capacity for Yukon (Target 160)
Date	Projected daily maximum testing capacity
2020-09-03	n/a
2020-09-10	n/a
2020-09-17	n/a
2020-09-24	n/a
2020-10-01	150
2020-10-08	150
2020-10-15	150
2020-10-22	150
2020-10-29	150
2020-11-03	150
2020-11-10	150
2020-11-17	150
2020-11-24	150
2020-12-01	150^Footnote*
2020-12-08	150^Footnote*
2020-12-15	150
2020-12-22	150
2020-12-22	150
2020-12-29	150
2021-01-05	150
2021-01-12	150
2021-01-19	150
2021-01-26	150^Footnote*
2021-02-02	150^Footnote*
2021-02-09	150
2021-02-16	150^Footnote*
2021-02-23	150^Footnote*
2021-03-02	150
2021-03-09	150^Footnote*
2021-03-16	150^Footnote*
2021-03-23	150
2021-03-29	150
2021-04-06	150
2021-04-12	150
2021-04-19	150
2021-04-26	150
2021-05-03	150
2021-05-10	150
2021-05-17	150
2021-05-24	150
2021-05-31	150
2021-06-30	150
2021-07-31	150
2021-08-31	150
2021-09-30	150

Northwest Territories: Target 225

COVID-19 testing capacity for Northwest Territories (Target 225)
Date	Projected daily maximum testing capacity
2020-09-03	n/a
2020-09-10	n/a
2020-09-17	n/a
2020-09-24	n/a
2020-10-01	48
2020-10-08	48
2020-10-15	48
2020-10-22	48
2020-10-29	75
2020-11-03	75
2020-11-10	75
2020-11-17	75
2020-11-24	75
2020-12-01	75^Footnote*
2020-12-08	75^Footnote*
2020-12-15	75^Footnote*
2020-12-22	75
2020-12-29	75
2021-01-05	75
2021-01-12	75
2021-01-19	75
2021-01-26	75*
2021-02-02	110
2021-02-09	110
2021-02-16	110
2021-02-23	110
2021-03-02	110
2021-03-09	110
2021-03-16	110
2021-03-23	110
2021-03-29	110
2021-04-06	110
2021-04-12	100
2021-04-19	110
2021-04-26	110
2021-05-03	110
2021-05-10	110
2021-05-17	110
2021-05-24	110
2021-05-31	110
2021-06-30	110
2021-07-31	110
2021-08-31	110
2021-09-30	110

Nunavut: Target n/a

COVID-19 testing capacity for Nunavut (Target n/a)
Date	Projected daily maximum testing capacity
2020-09-03	n/a
2020-09-10	n/a
2020-09-17	n/a
2020-09-24	n/a
2020-10-01	n/a
2020-10-08	n/a
2020-10-15	80
2020-10-22	80
2020-10-29	80
2020-11-03	100
2020-11-10	200
2020-11-17	200
2020-11-24	200
2020-12-01	200
2020-12-08	200
2020-12-15	250
2020-12-22	250
2020-12-29	250
2021-01-05	250
2021-01-12	250
2021-01-19	300
2021-01-26	300
2021-02-02	300
2021-02-09	300
2021-02-16	300
2021-02-23	300
2021-03-02	300
2021-03-09	300
2021-03-16	300
2021-03-23	300
2021-03-29	300
2021-04-06	300
2021-04-12	300
2021-04-19	300
2021-04-26	300
2021-05-03	300
2021-05-10	300
2021-05-17	300
2021-05-24	300
2021-05-31	300
2021-06-30	300
2021-07-31	300
2021-08-31	300
2021-09-30	300

Canada: Target 170,720 - 171,220

COVID-19 testing capacity for Canada (Target 170,720 - 171,220)
Date	Projected daily maximum testing capacity
2020-09-03	84,550
2020-09-10	89,951
2020-09-17	92,030
2020-09-24	94,049
2020-10-01	82,504
2020-10-08	113,046
2020-10-15	113,911
2020-10-22	128,838
2020-10-29	132,234
2020-11-03	141,072
2020-11-10	149,172
2020-11-17	153,064
2020-11-24	154,838
2020-12-01	155,309
2020-12-08	163,218
2020-12-15	169,036
2020-12-22	171,399
2020-12-29	172,997
2021-01-05	174,103
2021-01-12	215,545
2021-01-19	213,775
2021-01-26	216,930
2021-02-02	213,350
2021-02-09	216,159
2021-02-16	213,270
2021-02-23	218,560
2021-03-02	215,959
2021-03-09	219,131
2021-03-16	219,599
2021-03-23	222,124
2021-03-29	222,779
2021-04-06	225,534
2021-04-12	226,763
2021-04-19	227,701
2021-04-26	227,401
2021-05-03	235,213
2021-05-10	240,040
2021-05-17	240,413
2021-05-24	238,046
2021-05-31	238,280
2021-06-30	237,990
2021-07-31	237,990
2021-08-31	240,095
2021-09-30	238,091

Language selection

Search